Trial Search Results

Association Between a Multi-Gene Panel and Renal Denervation Effectiveness in Patients With Hypertension

The purpose of this study is to assess the effectiveness of a multi-gene panel to determine which subjects are likely to respond to renal denervation therapy with Medtronic's Symplicity Spyral™ multi-electrode renal denervation system.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Geneticure, LLC

Stanford Investigator(s):

Intervention(s):

  • Genetic: Geneticure for RDN Genetic Panel

Eligibility


Inclusion Criteria:

   1. Individual is currently or has previously been enrolled in a Medtronic clinical study
   utilizing the Symplicity Spyral™ multi-electrode renal denervation system.

   2. Subject received Renal Denervation.

   3. Subject has met the primary efficacy endpoint for the Medtronic Symplicity Spyral
   study and which arm they were randomized to.

   4. Individual agrees to have all study procedures performed, and is competent and willing
   to provide written, informed consent to participate in this clinical study.

Exclusion Criteria:

   - Unable to provide written, informed, consent

Ages Eligible for Study

18 Years - 80 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting